BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 12, Pages 1391-1397
Publisher
Informa UK Limited
Online
2017-10-16
DOI
10.1080/13543784.2017.1393518
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer
- (2017) Emmanuel S. Antonarakis EUROPEAN UROLOGY
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
- (2017) Matti Annala et al. EUROPEAN UROLOGY
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
- (2017) Hana Janouskova et al. NATURE MEDICINE
- Treatment strategies for DNA repair-deficient prostate cancer
- (2017) Benjamin A. Teply et al. Expert Review of Clinical Pharmacology
- AR Signaling and the PI3K Pathway in Prostate Cancer
- (2017) Megan Crumbaker et al. Cancers
- Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases
- (2016) Balasundaram Padmanabhan et al. JOURNAL OF BIOSCIENCES
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study
- (2016) Benjamin L. Maughan et al. PROSTATE
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
- (2016) E S Antonarakis et al. PROSTATE CANCER AND PROSTATIC DISEASES
- BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells
- (2016) Saeed Alghamdi et al. Stem Cell Research & Therapy
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Wnt5a Signaling in Cancer
- (2016) Marwa Asem et al. Cancers
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer
- (2015) Gretchen K. Hubbard et al. CANCER RESEARCH
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Non-canonical Bromodomain within DNA-PKcs Promotes DNA Damage Response and Radioresistance through Recognizing an IR-Induced Acetyl-Lysine on H2AX
- (2015) Li Wang et al. CHEMISTRY & BIOLOGY
- NF- B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
- (2015) N. Nadiminty et al. MOLECULAR CANCER THERAPEUTICS
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
- (2015) Siu Chiu Chan et al. NUCLEIC ACIDS RESEARCH
- RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
- (2015) D. T. Miyamoto et al. SCIENCE
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
- (2015) Anastasia Wyce et al. Oncotarget
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation
- (2014) Friederike Itzen et al. NUCLEIC ACIDS RESEARCH
- PTEN function: the long and the short of it
- (2014) Benjamin D. Hopkins et al. TRENDS IN BIOCHEMICAL SCIENCES
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
- (2013) Scott R. Floyd et al. NATURE
- Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
- (2013) Lina Gao et al. PLoS One
- Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy
- (2012) Gaetano Zafarana et al. CANCER
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
- (2011) S. Rahman et al. MOLECULAR AND CELLULAR BIOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic Lethality — A New Direction in Cancer-Drug Development
- (2009) J. Dirk Iglehart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1
- (2008) J. Zhu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More